Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,226 recruiting studies in this area right now.
By phase
- Not applicable9,543
- Phase 24,410
- Phase 12,677
- Phase 1/Phase 21,654
- Phase 31,397
- Phase 2/Phase 3284
- Phase 4261
Top conditions
- Breast Cancer1,200
- Prostate Cancer645
- Cancer635
- Colorectal Cancer480
- Lung Cancer418
- Ovarian Cancer338
- Multiple Myeloma330
- Pancreatic Cancer290
- Gastric Cancer281
- Acute Myeloid Leukemia280
- Hepatocellular Carcinoma256
- Solid Tumor246
- Advanced Solid Tumor232
- Head and Neck Cancer226
- Cervical Cancer225
- Endometrial Cancer210
- Advanced Solid Tumors203
- Esophageal Cancer191
Leading sponsors
- M.D. Anderson Cancer Center453
- Fudan University302
- National Cancer Institute (NCI)293
- Memorial Sloan Kettering Cancer Center291
- Sun Yat-sen University275
- Mayo Clinic238
- City of Hope Medical Center146
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences143
- AstraZeneca133
- Second Affiliated Hospital, Zhejiang University, School of Medicine128
Where studies are running
- California1,414
- Texas634
- Arizona507
- Florida437
- Alabama428
- New York406
- Massachusetts342
- Maryland329
- New Jersey273
- Pennsylvania232
Recruiting studies20,226 total
- NCT05319639RecruitingPhase 1/Phase 2
Irinotecan plus immunotherapy for stomach cancer
This Phase I/II trial tests how well irinotecan combined with tislelizumab (an immunotherapy) treats advanced stomach or gastroesophageal junction adenocarcinoma. It mainly looks at safety and the best way to use this combination, and may help shrink tumors or slow disease growth.
Fuzhou, FujianAges 18–75 - NCT05010681RecruitingPhase 2
Lenvatinib plus immunotherapy after prior liver cancer treatment
This Phase 2 trial tests lenvatinib combined with the immunotherapy drug sintilimab in people with advanced liver cancer who got worse after prior PD-1/PD-L1 treatment. It aims to slow cancer growth and improve outcomes after immune therapy hasn’t worked.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05384509Recruiting
Tracking antibody levels in cancer patients during COVID vaccines
This study measures COVID “neutralizing” antibodies over time in people with cancer who are on different kinds of cancer treatments. It aims to understand how vaccination and treatment type affect immune protection in cancer patients.
New Taipei CityAges 20 years+ - NCT06703632Recruiting
Testing a new stool test for early colon cancer detection
This study is evaluating PreveCol, a new second-line stool test for people aged 50–69 who had a positive FIT/FOBT result and are already scheduled for a colonoscopy. It aims to find out if this test can help detect colorectal cancer earlier.
Lisbon, Lisbon DistrictAges 50–69 - NCT06032845RecruitingPhase 2
Freezing tumors plus immunotherapy for advanced solid tumors
This trial tests if freezing tumor cells (cryoablation) combined with two drugs (tislelizumab and lenvatinib) can help people whose solid tumors have stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06783829RecruitingPhase 1
Study of SHR-4394 for men with advanced prostate cancer
This trial tests a new drug, SHR-4394, for men with prostate cancer that has spread to other parts of the body and is no longer responding to current treatments. The goal is to see if this drug can help slow down the cancer.
Chengdu, SichuanAges 18–85 - NCT06021678RecruitingPhase 1/Phase 2
EX103 for relapsed or refractory CD20-positive lymphoma
This trial tests a new drug called EX103 for people whose non-Hodgkin lymphoma (a cancer of the immune system) has come back or not responded to earlier treatments. The goal is to see if EX103 is safe and can shrink tumors.
Zhengzhou, HenanAges 18 years+ - NCT05749627Recruiting
Vaccine for advanced cancers using your tumor’s targets
This trial tests a personalized vaccine made from “neoantigens” (tumor-specific targets) to help your immune system fight advanced, inoperable solid tumors. It may be an option if standard treatment didn’t work or you stopped it and your health is strong enough for trial treatment.
Nanchang, JiangxiAges 18–70 - NCT06173219RecruitingPhase 1/Phase 2
Radiation and immunotherapy for advanced cancer
This trial tests combining two types of radiation therapy with an immunotherapy drug for people with advanced solid tumors that have spread or come back. The goal is to see if this approach can help when standard treatments have stopped working or aren’t an option.
Beijing, Beijing MunicipalityAges 18–75 - NCT06421324Recruiting
AI-guided health advice for stomach conditions
This trial tests whether a personalized AI program can give you better health advice based on your stomach condition. It is for people who have gastric intestinal metaplasia (GIM) or have had H. pylori infection and are already scheduled for a gastroscopy.
ValenciaAges 18 years+ - NCT07357207Enrolling by invitation
Video-immunotherapy for advanced breast cancer
This trial tests if a video-based immunotherapy approach can help treat locally advanced breast cancer. It is designed for people who can communicate in Turkish and are comfortable playing video games as part of their treatment.
Izmir, BalcovaAges 18 years+ - NCT07361224RecruitingPhase 1
Combining CLS-015 with CAR-T for large B-cell lymphoma
This trial tests combining an experimental drug (CLS-015) with a standard CAR-T cell therapy for people with large B-cell lymphoma whose disease is stable or progressing. It aims to see if the combination is safe and might improve treatment outcomes.
Tel AvivAges 18 years+ - NCT06605417Recruiting
Understanding Birthmark to Melanoma Changes
This study looks at how certain birthmarks (nevi) change over time and might turn into melanoma. By studying tissue samples, researchers hope to better understand this process.
MarseilleAges Any age - NCT06605443Recruiting
Precision medicine for large/giant congenital nevus and melanoma
This trial uses a precision medicine approach for people with melanoma. It studies how volatile organic compounds (substances your body releases) might help guide treatment for stage II, III, or IV melanoma.
BarcelonaAges 18 years+ - NCT06692972Recruiting
How lung cancer tumors change after high-dose radiation
This study looks at how the main lung tumor shrinks or changes after a complete course of high-dose radiation in people with stage II or III lung cancer. It uses scans taken before and after treatment to track the results.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07357519RecruitingPhase 1/Phase 2
Targeted radiation therapy for advanced osteosarcoma
This trial tests a new targeted radiation treatment (177Lu-TARGETed Osteosarcoma Therapy) for people with advanced osteosarcoma that has not responded to or has come back after prior chemotherapy. The goal is to see if this treatment can help shrink or control the cancer.
Los Angeles, CaliforniaAges 12 years+ - NCT07356531Recruiting
Thermosensitive Embolic Agent for Liver Cancer TACE
This trial tests a new heat-sensitive embolic agent used during TACE (a procedure that blocks blood flow to tumors and delivers chemotherapy directly to the liver) for primary liver cancer. It aims to see if the agent is safe and effective for patients who need TACE treatment.
Hefei, AnhuiAges 18–80 - NCT07359820RecruitingPhase 2
Lirafugratinib for solid tumors with FGFR2 fusion
This trial tests a targeted drug called lirafugratinib for people with advanced solid tumors (not bile duct cancer) that have a specific FGFR2 gene change. The drug blocks the faulty protein from helping the cancer grow.
Phoenix, ArizonaAges 18 years+ - NCT07358377RecruitingPhase 1
Combination therapy for HR-positive, HER2-negative cancer
This trial tests a new drug, HRS-6209, combined with other treatments for people with hormone receptor-positive, HER2-negative cancer. The goal is to see if the combination is safe and works well.
Bowral, New South WalesAges 18 years+ - NCT07354022RecruitingPhase 3
Study of HRS-8080 with dalpiciclib for advanced breast cancer after hormone therapy fails
This trial tests a new combination of drugs (HRS-8080 and dalpiciclib) for women with advanced or metastatic breast cancer that has stopped responding to initial hormone therapy after surgery. It aims to see if this combination is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT07361562RecruitingPhase 1
Study of CGT4255 for advanced solid tumors with HER2 changes
This trial tests an oral drug called CGT4255 for people with advanced solid tumors that have certain changes in the HER2 gene or related proteins. It aims to see if the drug is safe and effective.
Scottsdale, ArizonaAges 18 years+ - NCT07361497RecruitingPhase 3
New Drug vs Standard Drug After Chemoradiation for Stage 3 Lung Cancer
This study tests a new drug, pumitamig, against an older drug, durvalumab, for people with stage 3 non-small cell lung cancer that cannot be removed by surgery and has not progressed after chemotherapy and radiation. The goal is to see which drug works better to keep the cancer from growing.
Daphne, AlabamaAges 18 years+ - NCT07361003RecruitingPhase 3
Testing suvemcitug plus chemo for refractory colorectal cancer
This trial tests a new drug, suvemcitug, combined with an oral chemotherapy called FTD/TPI for people with advanced colorectal cancer that has stopped responding to standard treatments. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Fuzhou, FujianAges 18 years+ - NCT07356453RecruitingPhase 1
Study of PARG inhibitor FORX-428 for advanced solid tumors
This trial tests a new drug called FORX-428, which targets a protein called PARG, in people with advanced solid tumors. It is for patients whose cancer has not responded to prior treatments and who have specific genetic changes, such as BRCA mutations.
Palo Alto, CaliforniaAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,226 recruiting oncology studies from the U.S. registry right now, out of 30,453 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.